INNOVATE Corp. (VATE) kidney device shortlisted for top US Prix Galien award
Rhea-AI Filing Summary
INNOVATE Corp. reported that MediBeacon Inc., an equity method investment focused on fluorescent tracer agents and transdermal detection, has had its MediBeacon® TGFR™ System nominated by The Galien Foundation for the 2026 Prix Galien USA Best Medical Technology. The TGFR System is a first-in-kind point-of-care kidney function assessment platform using Lumitrace® (relmapirazin) injection, a monitor, and a reusable sensor to measure Glomerular Filtration Rate transdermally. Winners are scheduled to be announced at the 20th annual Prix Galien USA Awards Ceremony on October 29, 2026, in New York City. MediBeacon holds extensive intellectual property around this system and related technologies, and the TGFR System is approved for human use, with additional applications in other medical fields in various stages of clinical development.
Positive
- None.
Negative
- None.
Filing Explained
The August 18 Form 8-K records that MediBeacon’s TGFR System is nominated—not awarded—for the 2026 Prix Galien USA; winners are scheduled to be announced on October 29, 2026, and the nomination does not guarantee recognition.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Prix Galien awards ceremony date: October 29, 2026
Number of Prix Galien USA ceremonies: 20th annual
U.S. patents owned by MediBeacon: over 55
+4 more
7 metrics
Prix Galien awards ceremony date
October 29, 2026
Scheduled date of the 20th annual Prix Galien USA Awards Ceremony
Number of Prix Galien USA ceremonies
20th annual
Stated as the 20th annual Prix Galien USA Awards Ceremony
U.S. patents owned by MediBeacon
over 55
Granted U.S. patents covering the MediBeacon TGFR System and related technology
Worldwide patents owned by MediBeacon
over 275
Granted patents worldwide for TGFR System components and pyrazine platform uses
TGFR sensor reading rate
2.5 readings per second
TGFR Reusable Sensor recording frequency for fluorescent readings
INNOVATE employees
approximately 3,700
Employees across INNOVATE’s subsidiaries in infrastructure, life sciences, and spectrum
Press release date
August 18, 2026
Date of press release announcing the Prix Galien nomination
Key Terms
equity method investment, Glomerular Filtration Rate, transdermal, Prix Galien, +1 more
5 terms
equity method investment financial
"MediBeacon ... an equity method investment of INNOVATE"
An equity method investment is an accounting way to report ownership in another company when an investor has significant influence (commonly around 20–50% of voting rights). Instead of listing the other company’s full assets and debts, the investor records its share of that company’s profits or losses on its own income statement—like keeping track of your share of a neighborhood bakery’s monthly earnings. Investors care because those shared profits, losses and changes in the investee’s value directly affect the investor’s reported earnings and balance sheet, so this method can materially change a company’s financial picture and valuation.
Glomerular Filtration Rate medical
"The result is a transdermal assessment of Glomerular Filtration Rate (tGFR)"
Glomerular filtration rate (GFR) measures how well the kidneys filter waste from blood, expressed as the volume of blood cleared per minute; think of it like the flow rate through a coffee filter that tells you how quickly liquid is being cleaned. Investors care because GFR is a key clinical metric used to gauge patient health, determine drug dosing, qualify participants for trials, and influence regulatory decisions and market size for treatments related to kidney function.
transdermal medical
"enabling the assessment of kidney function by measuring ... transdermal assessment"
Transdermal describes a method of delivering a drug through the skin so the active ingredient is absorbed into the bloodstream, commonly via a patch, gel or cream. For investors, transdermal delivery affects a product’s convenience, steady dosing, patent and regulatory profile, manufacturing needs and market appeal—similar to a slow-release battery that makes a device easier to use and last longer, which can influence sales potential and risk.
Prix Galien medical
"The Prix Galien is widely regarded as the equivalent of the Nobel Prize"
forward-looking statements regulatory
"Certain statements in this press release may constitute “forward-looking statements”"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
FAQ
What did INNOVATE Corp. (VATE) announce regarding MediBeacon in this 8-K?
INNOVATE Corp. announced that its equity method investment MediBeacon’s MediBeacon TGFR System was nominated for the 2026 Prix Galien USA Best Medical Technology, a prestigious life sciences innovation award.
What is the MediBeacon TGFR System mentioned by INNOVATE Corp. (VATE)?
The MediBeacon TGFR System is a first-in-kind point-of-care kidney function assessment platform using Lumitrace (relmapirazin) injection, a monitor, and a reusable sensor to measure transdermal Glomerular Filtration Rate (tGFR).
What intellectual property does MediBeacon, linked to INNOVATE Corp. (VATE), hold?
MediBeacon owns over 55 granted U.S. patents and over 275 granted patents worldwide, covering the TGFR System, Lumitrace injection, sensor and algorithms, and other uses of its proprietary pyrazine platform and sensor technology.
How many people are employed across INNOVATE Corp. (VATE) subsidiaries?
INNOVATE states that it employs approximately 3,700 people across its subsidiaries, reflecting its portfolio presence in infrastructure, life sciences, and spectrum businesses.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| Date of Report (Date of Earliest Event Reported): | |||||
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||
| (Address of principal executive offices) | (Zip Code) | |||||||
| Registrant’s telephone number, including area code: | ( | |||||||
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||
| | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||
| | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||
| | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | ||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||
| N/A | ||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
| Emerging growth company | | |||||||
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | ☐ | ||||
| Item 8.01 | Other Events. | ||||
On August 18, 2026, the Company issued a press release titled "MediBeacon® Transdermal GFR System Nominated for 2026 Prix Galien USA Best Medical Technology”. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
| Item 9.01 | Financial Statements and Exhibits. | ||||
(d) Exhibits
Exhibit No. | Description | ||||
| 99.1 | Press Release dated August 18, 2026, titled “MediBeacon® Transdermal GFR System Nominated for 2026 Prix Galien USA Best Medical Technology” | ||||
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document). | ||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 18, 2026
INNOVATE Corp. (Registrant) | |||||||||||||||||
| By: | /s/ Michael J. Sena | ||||||||||||||||
| Name: Michael J. Sena | |||||||||||||||||
| Title: Chief Financial Officer | |||||||||||||||||
 |  | ||||
Exhibit 99.1
MediBeacon® Transdermal GFR System Nominated for 2026 Prix Galien USA Best Medical Technology
NEW YORK, August 18, 2026 (GLOBE NEWSWIRE) -- INNOVATE CORP.® (NYSE: VATE) (“INNOVATE”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, and an equity method investment of INNOVATE, announced that The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, has nominated the MediBeacon® TGFR™ System for the 2026 Prix Galien USA Best Medical Technology. The TGFR™ System is a first-in-kind product for point-of-care kidney function assessment. Winners will be announced at the 20th annual Prix Galien USA Awards Ceremony on October 29, 2026, at the American Museum of Natural History in New York City.
The TGFR™ System is comprised of a Lumitrace® (relmapirazin) injection, the TGFR™ Monitor, and a TGFR™ Reusable Sensor, enabling the assessment of kidney function by measuring the clearance rate of the fluorescent agent as it leaves the body. The result is a transdermal assessment of Glomerular Filtration Rate (tGFR), or kidney function. Earlier this year, the Journal of the American Society of Nephrology (JASN) also recognized a peer-reviewed transdermal GFR assessment article as one of five Editor's Choice articles of 2025.
About The Prix Galien
The Prix Galien is widely regarded as the equivalent of the Nobel Prize in biopharmaceutical research and life sciences. Created in France in 1970 by pharmacist Roland Mehl in honor of Claudius Galenus, the father of pharmacology and experimental physiology, it rewards outstanding achievements in life sciences innovation including new drugs, medical technologies, and digital health solutions that improve the state of human health. For more information, please visit: www.galienfoundation.org/prix-galien-usa.
About INNOVATE
INNOVATE is a portfolio of best-in-class assets in three key areas of the new economy – Infrastructure, Life Sciences and Spectrum. Dedicated to stakeholder capitalism, INNOVATE employs approximately 3,700 people across its subsidiaries. For more information, please visit: www.INNOVATECorp.com.
About MediBeacon Inc.
MediBeacon is a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection. MediBeacon’s use of proprietary fluorescent tracer agents coupled with transdermal detection technology focuses on providing vital and actionable assessment of organ function. MediBeacon owns over 55 granted U.S. patents and over 275 granted patents worldwide that provide extensive coverage of the MediBeacon® TGFR™ System, including Lumitrace® injection, the sensor and algorithms, as well as other strategic uses of its proprietary pyrazine platform and sensor technology. The TGFR System is approved for human use. Potential technology applications in gastroenterology, ophthalmology, and surgery are in various stages of clinical development. MediBeacon is based
in St. Louis, Missouri, with additional operations in Mannheim, Germany. For more information, please visit: www.medibeacon.com.
About Lumitrace® (relmapirazin) injection Relmapirazin is a non-radioactive, non-iodinated, pyrazine-based compound, which has been engineered to be inert, highly fluorescent, and have the clearance properties of a GFR tracer agent in the body. The unique photophysical characteristics of Lumitrace have been designed to enable the collection of fluorescence data via a photodetector sensor placed on the skin. Data collected by the sensor measures the change in the intensity of Lumitrace fluorescence over time and is converted into a transdermal GFR (tGFR) by proprietary algorithms. In a phase 2 investigational study, mGFR deduced from Lumitrace matched that of mGFR deduced from iohexol over a range of GFR values. See the peer reviewed article published in the October 2024 issue of Kidney International by Dorshow et al.
About the MediBeacon® TGFR™ System The MediBeacon® TGFR™ System is comprised of the TGFR™ Monitor, TGFR™ Reusable Sensor, TGFR™ Disposable Ring, and Lumitrace® (relmapirazin) injection, which together allow assessment of kidney function by measuring the clearance rate of the fluorescent agent as it leaves the body. The system records Lumitrace fluorescence intensity transdermally as a function of time via a sensor placed on the skin. The TGFR Reusable Sensor records 2.5 fluorescent readings per second and the TGFR Monitor will display the Average GFR reading at the point of care.
FOR IMPORTANT SAFETY INFORMATION FOR THE TGFR SYSTEM (U.S. FDA) see ifu.medibeacon.com.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements generally relate to future events, including, but not limited to, statements regarding the anticipated timing and location of the 2026 Prix Galien USA Awards Ceremony and the potential recognition of the MediBeacon® TGFR™ System as the Prix Galien USA Best Medical Technology award recipient. You are cautioned that such statements are not guarantees of future performance and that INNOVATE’s actual results may differ materially from those set forth in the forward-looking statements. All of these forward-looking statements are subject to risks and uncertainties that may change at any time. Factors that could cause INNOVATE’s actual expectations to differ materially from these forward-looking statements include the fact that a nomination for a Prix Galien USA award does not guarantee that the MediBeacon® TGFR™ System will receive the award, risks associated with managing growth related to increased operational size, the misuse by customers, physicians and technicians of MediBeacon’s products, and the ability of MediBeacon to effectively protect its intellectual property and the impact of a failure to do so and the other factors under the heading “Risk Factors” set forth in INNOVATE’s Annual Report on Form 10-K, as supplemented by INNOVATE’s quarterly reports on Form 10-Q, and in INNOVATE's Prospectus Supplement dated August 10, 2026. Such filings are available on our website or at www.sec.gov. You should not place undue reliance on these forward-looking statements, which are made only as of the date of this press release. INNOVATE undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent developments, events, or circumstances, except as may be required under applicable securities laws.
Investor Contact:
Solebury Strategic Communications Anthony Rozmus
(212) 235-2691
Email: ir@innovatecorp.com